Prognostic parameters in uveal melanoma: A review

Survey of Ophthalmology

Volumn 41, Issue 3, 1996, Pages 215-228

  Mooy, Cornelia M ^a,b   De Jong, P T V M ^b,c  

^a Department of Pathology ^*  (Netherlands)

^b ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^c NETHERLANDS INSTITUTE FOR NEUROSCIENCE   (Netherlands)

Author keywords

chromosome aberrations; genetics; immunology; melanoma; melanoma associated antigen; metastasis; uveal melanoma

Indexed keywords

DNA;

CANCER RISK; CANCER SURVIVAL; CHROMOSOME 3; DIAGNOSTIC ACCURACY; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; MELANOMA; PREDICTION; PRIORITY JOURNAL; REVIEW; TREATMENT PLANNING; UVEA TUMOR;

EID: 0030293855     PISSN: 00396257     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0039-6257(96)80024-5     Document Type: Article

References (137)

1. Adema GJ, de Boer AJ, van 't Hullenaar R, et al: Melanocytic lineage-specific antigens recognized by monoclonal antibodies NKI-beteb, HMB-50, and HMB-45 are encoded by a single cDNA. Am J Pathol 143:579-1585, 1993
2. Akslen IA, M rkve O: Expression of p53 protein in cutaneous melanoma. Int J Cancer 52:13-16, 1992
3. Albeda SM, Mette SA, Elder DE, et al: Integrin distribution in malignant melanoma: association of the 63 subunit with tumor progression. Cancer Res 50:6757-6764, 1990
4. Berge ten PJM, Danen EHJ, van Muijen GNP, et al: Integrines expression in uveal melanoma differs from cutaneous melanoma. Invest Ophthalmol Vis Sei 34:3635-3640, 1993
5. Bishop JM: Molecular themes in oncogenesis. Cell 64:235-248, 1991
6. Bock E: Cell-cell adhesion molecules. Biochem Soc Trans 19:1076-1080, 1991
7. Bosnian FT: Integrins: cell adhesives and modulators of cell function. Review. Histochem J 25:469-477, 1993
8. Burnier MN, McLean IW, Gamel JW: Immunohistochemical evaluation of uveal melanocytic tumors. Expression of HMB-45, S-100 protein, and neuron-specific enolase. Cancer 68:809-814, 1991
9. Callender GR: Malignant melanotyc tumors of the eye: A study of histologie types in 111 cases. Trans Am Acad Ophthalmol Otolaryngol 36:131-142, 1931
10. Carrel S, Schreyer M, Gross N, Zografos L.: Surface antigenie profile of uveal melanoma lesions analysed with a panel of monoclonal antibodies directed against cutaneous melanoma. Anticancer Res 10:81-89, 1990
11. Char DH, Huhta K, Waldman F: DNA cell cycle studies in uveal melanoma. Am J Ophthalmol 107:65-72, 1989
12. Char DH, Miller TR, Ljung BM, et al: Fine needle aspiration in uveal melanoma. Acta Cytologica 33:599-605, 1989
13. Chen TC, Char DH, Waldman F, Juster RP: Flow cytometry measurements of nuclear RNA content in uveal melanoma. Ophthalmic Res 22:187-193, 1990
14. Chevenix-Trench G, Martin NG, Ellem KA: Gene expres-sion in melanoma cell lines and cultured melanocytes: correlation between levels of c-src-1, c-myc and p-53. Oncogene 5:1187-1193, 1990
15. Coleman D), Silverman RH, Rondeau MJ, et al: Ultrasonic tissue characterization of uveal melanoma and prediction of patient survival after enucleation and brachytherapy. Am J Ophthalmol 112:682-688, 1991
16. Coleman K, van Diest PJ, Baak JP, Mullaney J: Syntactic structure analysis in uveal melanomas. Br J Ophthalmol 78: 871-874, 1994
17. Coleman K, Baak JPA, van Diest PJ, et al: DNA ploidy status in 84 ocular melanomas: a study of DNA quantitation in ocular melanomas by flow cytometry and automatic and interactive static image analysis. Hum Path 26:99-105, 1995
18. Coleman K, Baak JPA, Dorman A, et al: Deoxyribonnuclcic acid ploidy studies in choroidal melanomas. Am J Ophthalmol 115:376-383, 1993
19. Coleman K, Baak JPA, van Diest PJ, et al: Prognostic factors following enucleation of 111 uveal melanomas. Br J Ophthalmol 77:688-692, 1993
20. Cottam DW, Rees RC: Regulation of matrix metalloproteinases: their role in tumor invasion and metastasis. IntJ Oncol 2:861-872, 1993
21. Cottam DW, Rees RC, Parsons MA, et al: Degradative enzyme expression in uveal melanoma. Invest Ophthalmol Vis Sei 33:979, 1992
22. Cottam DW, Rennie IG, Rees RC: Cytokine modulation of gelatinase expression in a series of human melanoma cell lines. Cytokine 3:460, 1991
23. Cottain DW, Rennie IG, Woods K, et al: Gelatinolytic metalloproteinase secretion patterns in ocular melanoma pattern. Invest Ophthalmol Vis Sei 33:1923-1927, 1992
24. Crowley NJ, Seigier HF: Late recurrence of malignant melanoma.'Ann Surg 212: 17.3-177, 1990
25. de la Cruz. PO, Specht CS, McLean IW: Lymphocytic infiltration in uveal malignant melanoma. Cancer 65:112-115, 1990
26. Dahlenfors R, Tornqvist G, Wettrell K, Mark J: Cytogenetical observations in nine ocular malignant melanomas. Anticancer Res 13:1415-1420, 1993
27. Damato BE, Campbell AM, McGuire B], et al: Monoclonal antibodies to uveal melanomas. Eye 1:686-690, 1987
28. Danen EHJ, ten Berge PJM, van Muijen GNP, et al: Emergence of a5l fibronectin- and av3 vitronectin-receptor expression in melanocytic tumour progression. Histopathology 24:249-256, 1994
29. Dan K, Andreasen PA, Gr ndahl-Hansen J, et al: Plasminogen activators, tissue degradation and cancer. Adv Cancer Res 44:139-266, 1985
30. De Waard-Siebinga I, Blom DJR, Griffioen M, et al: Establishment and characterization of an uveal melanoma cell line. IntJ Cancer 62:155-161, 1995
31. De Waard-Siebinga I, Hilders CGJM, Hansen BE, el al: HLA expression and tumor-infiltrating immune cells in uveal melanoma. Graefe's Arch Clin Exp Ophthalmol 234: 34-42, 1996
32. Demon KJ, Stretch JR, Clatter KC, Harris AL: A study of adhesion molecules as markers of progression in malignant melanoma. J Pathol 167:187-191, 1992
33. Diener-West M, Hawkins B, Markowitx JA, Schachat AP: A review of mortality from choroidal melanoma. A meta-analysis of 5-year mortality rates following enucleation, 1966 through 1988. Arch Ophthalmol 110:245-250, 1992
34. Donoso IA, Shields JA, Augsburger JJ, et al: Antigenic and cellular heterogeneity of primary uveal malignant melanomas. Arch Ophthaimol 104:106-110, 1986
35. Durie FH, Campbell AM, Lee WR, Damato BE: Analysis of lymphocytic infiltration in uveal melanoma. Invest Ophthalmol Vis Sei 31:2106-2110, 1990
36. Egan K, Seddon J, Glynn R, et al: Epidemiologie aspects of uveal melanoma. Surv Ophthalmol 32:239-251, 1988
37. Eliopoulos AG, Kiaris H, Rees RC, et al: ras gene mutations are a rare event in human uveal and cutaneous melanomas. Oncol Reports 1:571-575, 1994
38. Fidler IJ: Critical factors in the biology of human cancer metastasis: 28th G.H.A. Clowes Memorial Award Lecture. Cancer Res 50:6130-6138. 1990
39. Filer RS, SongJC. Char DH, Kaleta-Michaels S: Uveal melanoma cylokines. Klin Monatshl Augenheilk 202:174-179, 1993
40. Folherg R, Oonoso LA, Atkinson BF, et al: An antimelanoma monoclonal antibody and the histopathology of uveal melanomas. Arch Ophthalmol 103:275-279. 1985
41. Folberg R, Gamel JW, Greenbeig RA, et al: Comparison of direct and microslide pathology measurements of uveal melanoma. Invest Ophthalmol Vis Sei 26:1788-1791, 1985
42. Folberg R, Rummelt V, Parys-Van Ginderdeuren R, et al: The prognostic value of tumor blood vessel morphology in primary uveal melanoma. Ophthalmology 100: 1389-1398,1993
43. Folberg R, Peer J, Gruman LM, et al: The morphologic characteristics of tumor blood vessels as a marker of tumor progression in primary human uveal melanoma: a matched case-control study. Hum Path 23:1298-1300. 1992
44. Fuchs U, Kivelä T, Summanen P, et al: An immunohistochemical and prognostic analysis of cytokeratin expression in malignant uveal melanoma. Am ( Pathol 141:169-181, 1992
45. Gamel JW, McGurdy JR, McLean IW: A compaiison of prognostic covariates for uveal melanoma. Invest Ophthalmol Vis Sei 33:1919-1922. 1992
46. Gamel JW, McLean IW: Quantitative analysis of Callcnder's classification of uveal melanoma cells. Arch Ophthalmol 95:686-691, 1977
47. Gamcl JW, Mcl.ean IW, Greenberg RA, et al: Computerized histologie assessment of malignant potential: a method for determining the prognosis of uveal melanomas. Hum Pathol 13:893-897, 1982
48. Gamel JW, McLean IW, McCurdy JR. Riologic distinctions between cure and time to death in 2892 patients with intraocular melanoma. Cancer 71:2299-2305. 1993
49. Gamel JW, Mcl-ean IW, Greenberg RA, et al: Objective assessment of the malignant potential of intraocular melanomas using standard H&E stained microslides. Hum Pathol 16:689-692, 1985
50. Gass JDM: Problems in the differential diagnosis of choroidal nevi and malignant melanomas. The XXXIII Edward Jackson Memorial Lecture. Am J Ophthalmol 83:299-323. 1977
51. Gown AM, Vogel AM, Hoak D, et al: Monoclonal antibodies specific for melanocytic tumors distinguish subpopulationsofmelanocytes. AmJ Pathol 123:195-203, 1986
52. Griffin CA, Long PP, Schachat AP: Irisomy 6p in ocular melanoma. Cancer Genet Cytogenet 32:129-132. 1988
53. Hall PA, Levison DA: Review: Assessment of cell proliferation in hislological material. J Clin Palhol 43:184-192, 1990
54. Holzmann B, Bröcker EB, Lehmann JM, et al: Tumor progression in human malignant melanoma: five stages defined by their antigenic phenotypes. Int J C-ancer 39:466-471,1987
55. Horsman DE, Sroka H, Rootman J, White VA: Monosomy 3 and isochrome 8Q in a uveal melanoma. Cancer Genet Cytogenet 45:249-253. 1990
56. Horsman DE, White VA: Cytogenetic analysis of uveal melanoma. Consistent occurrence of monosomy 3 and trisomy 8q. Cancer 71:811-819, 1993
57. Hunter T: Cooperation between oncogenes. Cell 64:249-270. 1991
58. Huntington A, Haugan P, Gamel J, McLean I: A simple cytological method for predicting the malignant potential of intraocular melanoma. Pathol Res Pract 185: 631-634. 1989
59. Jager MJ, van der Pol JP, de Wolff-Rouendaal D. et al: Decreased expression of HLA class II antigens on human uveal melanoma cells after in vivo X-ray irradiation. Am J Ophthalmol 105:78-86. 1988
60. Jay M, McCartney AC: Familial malignant melanoma of the uvea and p53: a Victorian detective story. Surv Ophlhalmol 37:456-462, 1993
61. Jensen OA, Andersen S: Spontaneous regression of a malignant melanoma of the choroid. Acta Ophthalmol 52: 173-181, 1974
62. Johnson JP: Oil adhesion molecules of the immunoglobulin supergene family and their role in malignant transformation and progression to metastatic disease. Cancer Metastasis Rev 10:11-22, 1991
63. Kamb A, Gruis NA, Weaver-Feldhans, et al: A cell cycle regulator potentially involved in genesis of many tumor types. Science 264:436-440, 1994
64. Kan-Mitchell J, Liggett PE, Taylor CR. et al: Differential SlOOb expression in choroidal and skin melanomas: Quantitation by the polymerase chain reaction. Invest Ophthalmol Vis Sei 34:3366-3375, 1993
65. Kan-Mitchell J, Rao N, Albert DM, ft al: S100 immunophenotypes of nveal melanomas. Invest Ophthalmol Vis Sei 31:1492-1496, 1990
66. Karlsson M, Boeryd B, Carstensen J, et al: DNA ploidy and S-phase fraction as prognostic factors in patients with uveal melanomas. Bi J Cancer 71:177-181, 1995
67. Kath R, Hayungs J, Bornfeld N, et al: Prognosis and treatment of disseminated uveal melanoma, (lancer 72:2219-2223, 1993
68. Klein CE, Steinmeyer T, Kaufmann R, et al: Identification of a melanoma progression antigen as integrin Vl.A-2. Invest Dermatol 96:281-284, 1991
69. Kovacs G: Abnormalities of chromosome no. 1 in human solid malignant tumors. IntJ Cancer 21:688-694, 1978
70. Langmann G, Kleiner! R, Wirnsberger GH, et al: Proliferationsmarkcr, Enlymmarker und Onkogenexpressionsprofile bei intraoknlaren Melanomen. Ophthalmologe 90: 528-532.1993
71. I.attman J, Kroll S, Char DH, et al: Cell cycling and prognosis in uveal melanoma. Clin Cane Res 1:41-47, 1995
72. Levine AJ, Moniand J, Fin lay CA: The p53 tumour-suppressor gene. Nature 351:453-456, 1991
73. Lollini P-L, De Giovanni C., Nicolletti G, et al: Enhancement of experimental metastatic ability by tumor necrosis factor-alpha alone or in combination with interferon-gamma. Clin Exp Metastasis 8:215-224, 1990
74. Luyten GPM, Mooy CM, Eijkenboom WMH, et al: No effect of pre-enucleation irradiation on survival of patients with uveal melanoma. Am J Ophthalmol 119:786-791, 1995
75. Luyten GPM, Naus NC, Mooy CM, et al: Establishment and characterization of primary and metastatic uveal melanoma cell lines. IntJ Cancer 66:380-387, 1996
76. Ma D, Luyten GPM, Luider TM, Niederkorn JY: Relationship between natural killer cell susceptibility and metastasis of human uveal melanoma cells in a murine model. Invest Ophthalmol Vis Sei 36:435-441. 1995
77. Marcus DM. Minkovitz JB, Wardwell SD, Albert DM: The val tie of nucleolar organizer regions in uveal melanoma. Am | Ophthalmol 110:527-534. 1990
78. Markowit JA, Hawkins BS, Diener-West M, Schachat AP: A review of mortality from choroidal melanoma. I. Quality of published reports, 1966 through 1988. Arch Ophthalmol 110:239-234. 1992
79. McCartney ACE, Marshall JF, Hart IR, Newton JA: Differential integrin expression and its role in the metastasis of ocular and cutaneous melanoma. Invest Ophthalmol Vis Sei 33:1437. 1992
80. McCurdy J. Camel J, McLean I: A simple, efficient and reproducible method for estimating the malignant potential of uveal melanoma from routine H & E slides. Pathol Res Pract 187:1025-1027, 1991
81. McLean IW: The biology of hacmatogeneous metastasis in human uveal melanoma. Virchows Arch A Pathol Anat 422:433-437, 1993
82. McLean IW: Discussion (Small choroidal melanocytic lesions). Ophthalmology 102:1361, 1995
83. McLean IW. Ainbinder DJ, Gamel JW, McCurdy JB: Cho-roidal-ciliary body melanoma. A mutivariate survival analysis of tumor location. Ophthalmology 102:1060-1064, 1995
84. McLean IW, Foster WD, Zimmerman LE: Uveal melanoma: location, size, cell type, and enucleation as risk factors in metastasis. Hum Pathol 13:123-132, 1982
85. McLean IW, Foster WD, Zimmerman LE, Camel JW: Modifications of Oallender's classification of uveal melanoma at the Armed Forces Institute of Pathology. AinJ Ophthalmol 96:502-509, 1983
86. McLean IW, Gamel JW: Prediction of metastasis of uveal melanoma. Comparison of morphometric determination of nucleolar size and spectrophotometric determination of DNA. Invest Ophthalmol Vis Sei 29:507-511, 1988
87. McLean IW, Zimmerman LE, Evans RM: Reappraisal of Callender's spindle A type of malignant melanoma of choroid and ciliary body. Am J Ophthalmol 86:557-564, 1978
88. Meecham WJ, Char DH: DNA content abnormalities and prognosis in uveal melanoma. Arch Ophthalmol 104:1626-1629, 1986
89. Meecham WJ, Char DH, Kaleta-Michaels S: Infiltrating lymphocytes and antigen expression in uveal melanoma. Ophthalmic Res 24:20-26, 1992
90. Mignatti P, Fifkin DB: Biology and biochemistry of proteinases in tumor invasion. Physiol Rev 73:161-195, 1993
91. Mooy CM, van der Helm MJ, van der Kwast TH, et al: No N-ra,s mutations in human uveal melanoma: the role of ultraviolet light revisited. BrJ Cancer 64:411-413, 1991
92. Mooy CM, de Jong PTVM, van der Kwast TH, et al: Ki-67 Immunostaining in uveal melanoma: the effect of pre-enucleation radiotherapy. Ophthalmology 97:1275-1280, 1990
93. Mooy CM, Luvten CPM, l.uider TM, et al: An immunohistochemical and prognostic analysis of apoptosis and proliferation in uveal melanoma. Am J Pathol 147:1097-1104, 1995
94. Mooy CM, Luyten CPM, de Jong PTVM, et al: Neural cell adhesion molecule distribution in primary and metastatic uveal melanoma. Hum Pathol 26:1185-1190, 1995
95. Mooy C, Vissers K, Mvilder A, et al: DNA flow cytometry in uveal melanoma: the effect of pre-enucleation radiotherapy. BrJ Ophthalmol 79:174-177, 1995
96. Muijen van C-NP, Ruiter DJ, Hoefakker S, Johnson JP: Monoclonal antibody PAL-MI reconizes the transferrin receptor and is a progression marker in melanocytic lesions. J Invest Dermatol 95:65-69, 1990
97. Natali PC, Bigotti A, Nicotra MR, et al: Analysis of the antigenic profile of uveal melanoma lesions with anti-cutaneous melanoma-associated antigen and anti-HIA monoclonal antibodies. Cancer Res 49:1269-1274, 1989
98. Nicolson CL: Organ specificity of tumor metastasis: role of preferential adhesion, invasion and growth of malignant cells at specific sites. Cancer Metastasis Rev 7:143-188, 1988
99. Ordonez NC, Xiaolong [, Hickey RC: Comparison of HMB-45 monoclonal antibody and S100 protein in the immuuohistochemical diagnosis of melanoma. Am J Clin Pathol 90:385-390, 1988
100. Pathak S, Drwinga HL, Hsu TC: Involvement of chromosome 6 in rearrangements in human malignant melanoma cell lines. Cytogenet Cell Cenet 36:573-579, 1983
101. Pedersen MI, Wang N: Chromosomal evolution in the progression and metastasis of human malignant melanoma. A multiple lesion study. Cancer Genet Cytogenet 41:185-201, 1989
102. Pe'er J, Gnessin H, Shargal Y, Livni N: PC-10 immunostaining of proliferating cell nuclear antigen in posterior uveal melanoma. Ophthalmology 101:56-62, 1994
103. Pe'er J, Rummelt V, Mawn L, et al: Mean of the ten largest nucleoli, microcirculation architecture and prognosis of ciliochoroidal melanomas. Ophthalmology 101:1227-1235, 1994
104. van der Pol JP, Jager MJ, de Wolff-Rouendaal D, et al: Heterogeneous expression of melanoma-associated antigens in uveal melanomas. Curr Eye Res 6:757-765, 1987
105. Prescher G, Bornfeld N, Becher R: Nonrandom chromosomal abnormalities in primary uveal melanoma. J Natl Cancer Inst 82:1765-1769, 1990
106. Prescher G, Bornfeld N, Horsthemke B, Becher R: Chromosomal aberrations defining uveal melanoma of poor prognosis. Lancet 339:691-692, 1992
107. Prescher G, Borniekl N, Hirche H, et al: Prognostic implications of monosomy 3 in uveal melanoma. Lancet 347: 1222-1225, 1996
108. Qninn LA, Woods LK, Merrick SB, et al: Cytogenetic analysis of twelve human malignant melanoma cell lines. J Natl Cancer Inst 59:301-307, 1977
109. Ringens P), van Haperen R, Vennegoor C., et al: Monoclonal antibodies in detection of choroidal melanoma. Graefe's Arch Clin Exp Ophthalmol 227:287-290, 1989
110. Rennie IG, Rees RC, Parsons MA, et al: Estimation of DNA content in uveal melanoma by flow cytometry. Eye 3:611-617, 1989
111. Royds JA, Sharrard RM, Parsons MA, et al: C-myc oncogene expression in ocular melanomas. Gracies Arch Clin Exp Ophthalmol 230:366-371, 1992
112. Ruiter DJ, Bergman W, Welvaart K, et al: Immunohistochemical analysis of malignant melanomas and nevocellular nevi with monoclonal antibodies to distinct monomorphic determinants of HLA antigens. Cancer Res 44:3930-3935, 1984
113. Rummelt V, Folberg R, Woolson RP, et al: Relation between the microcirculation architecture and the aggressive behavior of ciliary body melanomas. Ophthalmology 102: 844-851, 1995
114. Rummelt V, Folberg R, Rummelt C, et al: Microcircnlation architecture of melanocytic nevi and malignant melanomas of the ciliary body and choroid. a comparative histopathologic and ultrastructnral study. Ophthalmology 101: 718-727, 1994
115. Rusciano D, Burger MM: Why do cancer cells metastasize into particular organs? Bioessays 14:185-194, 1992
116. Seddon JM, Albert DM, Lavin PT, Robinson N: A prognostic factor study of disease-free interval and survival following enucleation for nveal melanoma. Arch Ophthalmol 101:1894-1899, 1983
117. Seddon JM, Polivogianis I., Hsieh CC, et al: Death from uveal melanoma. Number of epithelioid cells and inverse S.D. of nucleolar area as prognostic factors. Arch Ophthalmol 105:801-806, 1987
118. Shields JA, Shields CL: Current management of posterior uveal melanoma. Mayo Clin Proc 68:1196-1200, 1993
119. Shields JA, Shields CL, Donoso LA: Management of posterior uveal melanoma. Major review. Surv Ophthalmol 36: 161-195, 1991
120. Shields JA, Shields CL, Ehya H, et al: Fine-needle aspiration biopsy of suspected intra-ocular tumors. The 1992 Urwick Lecture. Ophthalmology 100:1677-1684, 1993
121. Shields CL, Shields JA, Kiratli H, et al: Risk factors for growth and metastasis of small choroidal melanocytic lesions. Ophthalmology 102:1351-1361, 1995
122. Sisley K, Rennie IG, Cottam DW, et al: Cytogenetic findings in six posterior uveal melanomas: Involvement of chromosome 3,6 and 8. Genes, Chromosomes & Cancer 2: 205-209, 1990
123. Smoller BR, McNutt NS, Hsu A: HMB-45 recoguizes stimulated melanocytes. J Oman Pathol 16:49-53, 1989
124. Soparker CN, O'Brien JM, Albert DM: Investigation of the role of the ras proto-oncogene point mutation in human uveal melanomas. Invest Ophthalmol Vis Sci 34:2203-2209, 1993
125. Steuhl KP, Rohrbach JM, Knorr M. Thiel HJ: Significance, specificity and ultrastructural localization of HMB-45 antigen in pigmented ocular tumors. Ophthalmology 100:208-215, 1993
126. Stretch JR, Gatter KG, Ralfkiaer E, et al: Expression of mutant p53 in melanoma. Cancer Res 51:5976-5979, 1991
127. Tobal K, Warren W, Cooper CS, et al.: Increased expres-sion and mutation of p53 in rhoroidal melanoma. Br J Cancer 66:990-904, 1992
128. Trent JM: Cytogenetics of human malignant melanoma. Cancer Metastasis Rev 10:103-113, 1991
129. Trent JM, Meyskens FL, Salmon SE, et al: Relation of cytogenetic abnormalities and clinical outcome in metastatic melanoma. N EnglJ Med 322:1508-1511, 1990
130. Trent JM, Thompson FH, Meyskens FLJr: Identification of a recurring translocation site involving chromosome 6 in human malignant melanoma. Cancer Res 49:420-423, 1988
131. Veer van't LJ, Burgering BMT, Versteeg R, et al: N-ras mutations in human cutaneous melanoma from sun exposed body sites. Mol Cell Biol 9:3114-3116, 1989
132. Vennegoor C, Hageman Ph, van Nouhuijs H, et al: A monoclonal antibody specific for cells of the melanocytic lineage. Am J Pathol 130:179-192, 1988
133. Vries de TJ, Mooy CM, van Balken MR, et al: Components of the plasminogen activation system in uveal melanoma: a clinico-pathological study. J Pathol 175:59-67, 1995
134. Vries de TJ, Quax PHA, Denijn M, et al: Plasminogen activators, their inhibitors,and urokinase receptor emerge in late stages of melanocytic tumor progression. Am J Pathol 144:70-81, 1994
135. Whelchel JC, Farah SE, McLean IW, Bnrnier MN: Immunohistochemistry of infiltrating lymphocytes in uveal malignant melanoma. Invest Ophthalmol Vis Sei 34:2603-2606, 1993
136. Wiltshire RN, Einer VM, Dennis T, et al: Cytogenetic analysis of posterior uveal melanoma. Cancer Genet Cytogenet 66:47-53, 1993
137. Wynford-Thomas D. Editorial. P53 in tumour pathology: can we trust immunocytochemistry? J Pathol 166:329-330, 1992